Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 91 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Ingredient Group Clear all
Active, not recruiting Phase 1 Interventional

Effects of Repeated Psilocybin Dosing in OCD

NCT05370911
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

NCT01139450
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
8 Years and older
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 29, 2026, 9:50 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

NCT05590468
View directory record Official record
Conditions
Mitochondrial Myopathy
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement · Drug
Lead sponsor
Ralitza Gavrilova
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

NCT04766723
View directory record Official record
Conditions
Essential Tremor of the Upper Limb
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Tampa, Florida • Omaha, Nebraska • Las Vegas, Nevada + 6 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Terminated Phase 3 Interventional

A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer

NCT02667327
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Granexin gel, Vehicle gel
Drug · Other
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Doral, Florida • Hialeah, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of AMP Human Sodium Bicarbonate Lotion on Dehydrated Heat Stress

NCT05092854
View directory record Official record
Conditions
Fluid Retention, Sodium Retention, Heat Stress, Dehydration (Physiology), Renal Injury, Electrolyte and Fluid Balance Conditions
Interventions
PR Lotion - AMP Human Performance, Placebo Lotion, AminoVital - Rapid Recovery, Placebo Supplement
Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 29, 2026, 9:50 PM EDT
Recruiting Phase 3 Interventional

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

NCT07201129
View directory record Official record
Conditions
Nephritis, Lupus, Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
14
States / cities
Doral, Florida • Kissimmee, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

NCT04313400
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2
Drug
Lead sponsor
Amytrx Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Cerritos, California • Encino, California • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 4 Interventional Results available

Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)

NCT04811339
View directory record Official record
Conditions
Diarrhea, COVID-19
Interventions
Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable, Placebo oral tablet without BSS
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

NCT03176472
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
ricolinostat, Placebo
Drug
Lead sponsor
Regenacy Pharmaceuticals LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 29, 2026, 9:50 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

NCT06073132
View directory record Official record
Conditions
Generalized Epidermolysis Bullosa Simplex
Interventions
AC-203, Vehicle
Drug
Lead sponsor
TWi Biotechnology, Inc.
Industry
Eligibility
6 Months and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Rancho Santa Margarita, California • Stanford, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

NCT02120898
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod, Zyclara®, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 29, 2026, 9:50 PM EDT
Recruiting Phase 3 Interventional

Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology

NCT05206955
View directory record Official record
Conditions
Fontan Palliation
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Testing a Non-Deceptive Placebo Intervention for Subclinical Depressive Symptoms

NCT07889908
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Psychological Distress, Depression / Major Depressive Disorder
Interventions
Non-deceptive placebo (NDP)
Other
Lead sponsor
Miami University
Other
Eligibility
18 Years to 30 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Oxford, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin D Absorbance Study - Clinical Trial of the Absorbance of Nano Liquid D3

NCT04885803
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Softgel Vitamin D3, Nano Liquid Vitamin D3, 25(OH)D Blood Serum Test, Placebo Control
Dietary Supplement · Diagnostic Test · Other
Lead sponsor
Inspired Life Medical, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Le Sueur, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 2 Interventional Results available

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

NCT00628095
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CE-224,535, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Mesa, Arizona • DeBary, Florida • Lake Mary, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia

NCT05655819
View directory record Official record
Conditions
Functional Dyspepsia
Interventions
Glutamine, Placebo
Drug
Lead sponsor
David J. Cangemi
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria

NCT02194621
View directory record Official record
Conditions
Oral Bacteria Levels in the Mouth
Interventions
Total Flavor option 1, Total Flavor option 2, Placebo toothpaste: Crest Cavity Protection toothpaste
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
22 Years to 58 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 29, 2026, 9:50 PM EDT
Terminated Phase 2 Interventional Results available

COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes

NCT04537299
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 29, 2026, 9:50 PM EDT
Recruiting Not applicable Interventional

A Study of Music Therapy for Anxiety in People With Cancer

NCT07845422
View directory record Official record
Conditions
Cancer
Interventions
AI-Assisted Collaborative Songwriting (ARTIST) Intervention, Time and attention matched-music listening (TAME)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Three Toothpastes for the Prevention and Reduction of White Spot Lesions

NCT03440996
View directory record Official record
Conditions
White Spot Lesion, Orthodontic Treatment, Decalcification; Teeth
Interventions
Clinpro™ 5000, Clinpro™ Tooth Crème, MI-Paste Plus
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
12 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Gut-brain Axis in Food Reward and Alcohol Consumption

NCT01902069
View directory record Official record
Conditions
Impulsivity, Alcohol Consumption
Interventions
Phospholean, Placebo
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 29, 2026, 9:50 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 29, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

NCT01520909
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Year to 17 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Los Angeles, California • St. Petersburg, Florida • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 29, 2026, 9:50 PM EDT